BASECARE-B's Embryo Culture Medium Receives Chinese Regulatory Approval

Stock News
02/26

BASECARE-B (02170) has announced that its Geri embryo culture medium, a product within the Gems embryo culture series, received a Class III Medical Device Registration Certificate from China's National Medical Products Administration on February 25, 2026. Prior to this approval, the Geri embryo culture medium had already obtained certifications from European CE, the U.S. Food and Drug Administration, and Australia's Therapeutic Goods Administration. The core technology for this product originates from the Sydney IVF Centre.

Integrated with the Geri time-lapse incubator and an AI embryo evaluation system, the Geri embryo culture medium has now entered clinical practice in China. It addresses challenges in embryo cultivation for older patients through its two core advantages: an antioxidant formulation and a stable osmotic pressure environment. The technical focus of the Geri culture medium lies in providing a systematic solution tailored to the reproductive difficulties faced by older patients. Its "triple antioxidant protection network" effectively mitigates oxidative stress in embryos from older patients. Combined with pre-added human serum albumin and long-term stability, it significantly simplifies laboratory procedures and ensures a consistent culture environment.

International clinical validation indicates that when used with the Geri time-lapse incubator and AI embryo evaluation system, this culture medium can notably increase the rates of high-quality blastocyst formation and clinical pregnancy, offering robust support for advanced-age fertility. This approval marks a critical step for the company in transitioning from technology introduction to localized production, filling a gap in domestically produced high-end assisted reproductive consumables. BASECARE-B has become the first Chinese company to hold four major international certifications: FDA, CE, TGA, and NMPA. Leveraging its core PGT technology and in-house supply capacity for consumables, the company now serves the vast majority of licensed PGT institutions across China and has established dozens of localized laboratories, creating a continuously evolving ecosystem barrier.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10